Superficial Spreading Melanoma: Clinical Features, Staging, and Treatment

Clinical Overview

Superficial spreading melanoma (SSM) is the most common histologic variant of cutaneous melanoma, representing 60-70% of all melanoma cases. SSM is characterized by a predominantly horizontal growth pattern confined to the epidermis and superficial dermis, distinguishing it from nodular and other melanoma subtypes. The defining feature is an extended radial growth phase (RGP) before transition to vertical growth phase (VGP), which correlates with more favorable clinical outcomes compared to nodular melanoma. Early detection during the SSM RGP offers the best opportunity for complete cure.

Epidemiology & Risk Factors

SSM occurs in 40-50 year-old individuals on average, slightly older than acral lentiginous melanoma but younger than lentigo maligna melanoma. Predisposing factors include: chronic intermittent sun exposure (particularly with history of sunburns), fair skin phototype (Fitzpatrick I-II), family history of melanoma, multiple dysplastic nevi (>50 nevi), and personal history of melanoma. Unlike lentigo maligna, SSM typically occurs on trunk and proximal extremities with variable pigmentation backgrounds. The lifetime risk of developing melanoma increases dramatically with >5 atypical moles, approaching 40% in individuals with dysplastic nevus syndrome and positive family history.

Pathophysiology

SSM arises through malignant transformation of melanocytes within the basal layer of the epidermis. The tumor demonstrates initial horizontal growth confined to the intraepidermal and superficial dermal compartments during the radial growth phase. Histologically, SSM shows: variable cellularity with melanocytes infiltrating all levels of the epidermis (pagetoid spread), cytologic atypia with nuclear pleomorphism and increased mitotic activity, and prominent lymphocytic infiltrate. The transition to vertical growth phase is marked by the appearance of melanocytes in the deep dermis and subcutaneous tissue with expansile nodular growth. Key molecular alterations include BRAF V600E mutations (present in ~60% of SSM cases), NRAS mutations (~20%), and KIT mutations (~10%). Loss of p16 expression correlates with progression to VGP.

Clinical Presentation & Classification

SSM typically presents as an irregularly shaped lesion with asymmetry, variable coloration, and poorly defined borders—features consistent with the ABCDE criteria (Asymmetry, Border irregularity, Color variation, Diameter >6mm, Evolving/changing). The lesion frequently displays multiple colors including tan, brown, black, and red/pink areas due to varying degrees of melanin production and inflammation. Early lesions may appear as subtle patches with minimal elevation. The lesion evolves over months to years, with gradual increase in size and darkening. Transition to VGP manifests as nodule formation, surface elevation, or development of darkly pigmented papule within the patch. Some SSM lesions present with regression—white scarring that may indicate host immune response and can be associated with favorable prognosis.

Diagnosis & Staging

Clinical diagnosis requires dermoscopy, which reveals characteristic features: atypical network pattern with thick brown lines and irregular meshes, irregular dots and globules (particularly at periphery), irregular streaks, and blue-gray veil representing superficial dermal involvement. Diagnosis is confirmed by excisional biopsy with narrow margins (1-3mm) to allow complete histopathologic assessment of Breslow depth and Clark level. Breslow depth measurement is critical for staging: lesions ≤0.8mm (Stage IA), 0.81-1.0mm (Stage IB), 1.01-2.0mm (Stage IIA), 2.01-4.0mm (Stage IIB), and >4.0mm (Stage IIC). Clark level indicates invasion: I (confined to epidermis, in situ), II (into papillary dermis), III (filling papillary dermis), IV (into reticular dermis), and V (into subcutaneous fat). Mitotic rate (≥1 mitosis/mm² increases stage), and ulceration status determine final TNM stage. Sentinel lymph node (SLN) biopsy is recommended for Stage IB-II melanoma (Breslow 0.8-4.0mm), as it provides accurate staging and potential therapeutic benefit.

Treatment Algorithm

Surgical excision remains the cornerstone of treatment for localized SSM. After confirmatory excisional biopsy, re-excision with appropriate margins is performed: 0.5-1.0cm for tumors ≤1.0mm Breslow depth, 1.0cm for tumors 1.01-2.0mm, and 1-2cm for tumors 2.01-4.0mm. Complete lymph node dissection is considered for SLN-positive disease. For Stage III melanoma with locoregional metastases, adjuvant immunotherapy with ipilimumab (Yervoy) at 3mg/kg intravenously every 3 weeks for 4 doses, followed by maintenance at 3mg/kg every 12 weeks (maximum 2 years) improves recurrence-free survival (RFS) from 50% to 70% at 3 years (CheckMate 069). Alternatively, pembrolizumab (Keytruda) 200mg intravenously every 3 weeks for up to 1 year achieves similar RFS benefit (KEYNOTE-054). Dabrafenib (100mg twice daily) plus trametinib (2mg daily) is utilized for BRAF-mutant advanced disease, achieving response rates of 64% (COMBI-d trial). For advanced Stage IIC-IV disease, nivolumab (Opdivo) 3mg/kg IV every 2 weeks or pembrolizumab 2mg/kg IV every 3 weeks is indicated, with combination nivolumab plus ipilimumab producing superior overall survival (OS) compared to single agents (median OS >60 months in responders).

Prognosis & Survival

SSM prognosis depends primarily on Breslow depth. Ten-year melanoma-specific survival for Stage IA (≤0.8mm) approximates 95%, Stage IB (0.81-1.0mm) is 90%, Stage IIA (1.01-2.0mm) is 80%, Stage IIB (2.01-4.0mm) is 65%, and Stage IIC (>4.0mm) drops to 40%. SLN positivity reduces 5-year survival by 20-30% depending on burden of metastatic disease. Presence of ulceration reduces survival by approximately 10% within each stage group. Mitotic rate ≥1/mm² adversely affects prognosis. Distant metastatic disease (Stage IV) has median survival of 8-12 months with single-agent immunotherapy, improving to 18-24 months with combination nivolumab-ipilimumab. Patients with BRAF V600E mutations treated with BRAF/MEK inhibitors achieve median progression-free survival of 11-12 months.

When to See a Dermatologist

Dermatology evaluation is indicated for any new or changing pigmented lesion, particularly those meeting ABCDE criteria. Surveillance interval depends on risk stratification: patients with 10-50 dysplastic nevi require examination every 3-6 months, those with >50 nevi or personal history of melanoma require examination every 1-3 months, and those with familial melanoma syndrome require examination every 1-2 months. Total-body skin examination with dermoscopy and photographic documentation enhances detection of interval melanomas. Referral to surgical oncology or medical oncology is indicated for melanoma with Breslow depth ≥0.8mm, SLN positivity, or distant metastases.

Frequently Asked Questions

What is the difference between superficial spreading melanoma and other melanoma types?

SSM differs from nodular melanoma by having an extended horizontal growth phase before vertical invasion; nodular melanoma lacks this RGP and presents at deeper invasion levels, resulting in poorer prognosis. Lentigo maligna occurs on sun-damaged skin of elderly patients and has slower growth; acral lentiginous melanoma involves palms, soles, and nailbeds with distinctly different histology. Desmoplastic melanoma is rare and characterized by fibrosis with neurotropism.

If my Breslow depth is 1.2mm, do I need sentinel lymph node biopsy?

Yes. Current American Academy of Dermatology (AAD) guidelines recommend SLN biopsy for intermediate-thickness melanoma (Breslow 0.8-4.0mm) to determine accurate staging and identify locoregional metastases. SLN positivity changes management—SLN-positive patients benefit from adjuvant immunotherapy even if no macroscopic nodal disease is detected on imaging. However, discussion of SLN biopsy risks/benefits is appropriate for borderline cases (0.8-1.0mm).

What is my risk of recurrence after complete surgical excision at Stage IIA?

Stage IIA melanoma (Breslow 1.01-2.0mm, no ulceration) has approximately 80% 10-year survival and 50-60% risk of recurrence without adjuvant therapy. Adjuvant pembrolizumab or high-dose interferon improves recurrence-free survival by 20-25%. With adjuvant immunotherapy, approximately 70% of Stage IIA patients remain recurrence-free at 2 years. Recurrence patterns include in-transit metastases (20-30%), locoregional nodal disease (20-30%), and distant metastases (10-20%).

Are there genetic tests that predict my melanoma outcome?

Current prognostic genetic markers include BRAF, NRAS, and c-KIT mutation status, which guide systemic therapy selection. BRAF-mutant melanoma responds to dabrafenib-trametinib, while NRAS-mutant disease may respond to MEK inhibitors (selumetinib, binimetinib). Gene expression profile testing (DecisionDx-Melanoma) stratifies low-risk versus high-risk disease and can inform surveillance intensity, though clinical utility remains evolving. Microsatellite instability (MSI-high) predicts superior immunotherapy response.

References

  1. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3622-3634.
  2. Garbe C, Peris K, Ascierto PA, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline—Update 2019. Eur J Cancer. 2020;126:159-177.
  3. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo in resected Stage III IIM melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522-530.
  4. Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus Merck's anti-PD-L1 Keytruda (pembrolizumab) versus placebo plus Keytruda in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2022;400(10368):1682-1696.
  5. Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813-1823.
  6. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.
  7. Sladden MJ, Balch C, Barzilai DA, et al. Surgical excision margins for primary cutaneous melanoma. J Am Acad Dermatol. 2012;66(3):395-404.
  8. Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208-250.
  9. Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Khattak A. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(5):v126-v132.
  10. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer staging system. J Clin Oncol. 2001;19(16):3622-3634.

Last updated: March 2026. This article reflects current evidence-based clinical practice and is intended for healthcare professionals and informed patients. Always consult with a board-certified dermatologist for personalized medical advice.